Development of neutralizing antibodies against SARS-CoV-2, using a high-throughput single-B-cell cloning method

BACKGROUND: Rapid and efficient strategies are needed to discover neutralizing antibodies (nAbs) from B cells derived from virus-infected patients. METHODS: Here, we report a high-throughput single-B-cell cloning method for high-throughput isolation of nAbs targeting diverse epitopes on the SARS-CoV...

Descripción completa

Detalles Bibliográficos
Autores principales: Dou, Yang, Xu, Ke, Deng, Yong-Qiang, Jia, Zijing, Lan, Jun, Xu, Xiaoyu, Zhang, Guorui, Cao, Tianshu, Liu, Pan, Wang, Xiangxi, Wang, Xinquan, Xu, Lingjie, Du, Pan, Qin, Cheng-Feng, Liu, Hong, Li, Yafeng, Wu, Guizhen, Wang, Kang, Lu, Bai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108556/
https://www.ncbi.nlm.nih.gov/pubmed/37077472
http://dx.doi.org/10.1093/abt/tbad002
Descripción
Sumario:BACKGROUND: Rapid and efficient strategies are needed to discover neutralizing antibodies (nAbs) from B cells derived from virus-infected patients. METHODS: Here, we report a high-throughput single-B-cell cloning method for high-throughput isolation of nAbs targeting diverse epitopes on the SARS-CoV-2-RBD (receptor binding domain) from convalescent COVID-19 patients. This method is simple, fast and highly efficient in generating SARS-CoV-2-neutralizing antibodies from COVID-19 patients’ B cells. RESULTS: Using this method, we have developed multiple nAbs against distinct SARS-CoV-2-RBD epitopes. CryoEM and crystallography revealed precisely how they bind RBD. In live virus assay, these nAbs are effective in blocking viral entry to the host cells. CONCLUSION: This simple and efficient method may be useful in developing human therapeutic antibodies for other diseases and next pandemic.

Ejemplares similares